Evusheld approved in the EU for COVID-19
28 March 2022 07:00 BST Evusheld long-acting antibody combination approved in the EU forpre-exposure prophylaxis (prevention) of COVID-19 in a broad population Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase IIItrial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 subvariant,now the dominant strain in Europe AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been granted marketing authorisation in the European Union